Winn-Dixie (WINN) (DG) (VRA) (DOLE) (MYGN) (EMC) EPS Estimates Changed

Winn-Dixie (NASDAQ:WINN), Dollar General (NYSE:DG), Vera Bradley (NASDAQ:VRA), Dole Food (NYSE:DOLE), Myriad Genetics (NASDAQ:MYGN) and EMC (NYSE:EMC) EPS estimates adjusted by analysts.

Winn-Dixie EPS estimates were lowered by analysts through 2012 by BMO Capital Markets. They reiterate a "Market Perform" rating and price target of $9 on the company.

Dollar General EPS estimates were boosted by BMO Capital Markets through 2012. They maintain an "Outperform" rating and price target of $40 on the company.

Vera Bradley had its EPS estimates raised by KeyBanc through 2012. They reiterate their "Buy" rating and price target of $48 on the company.

Dole Food had its EPS estimates cut by Goldman Sachs (NYSE:GS). They have a "Neutral" rating and price target of $12 on the company.

Myriad Genetics had its EPS estimates raised by Goldman Sachs. They have a "Sell" rating and price target of $19 on the company.

EMC had its EPS estimates lowered through 2012 by Credit Suisse (NYSE:CS). They have an "Outperform" rating and a price target $27 on the company.

SunPower (SPWRA) (DIS) (GM) (ACAS) (BWC) (CTL) (HUM) (MYGN) EPS Estimates Changed

SunPower Co. (NASDAQ: SPWRA), Walt Disney (NYSE: DIS), General Motors (NYSE: GM), American Capital (NASDAQ: ACAS), Babcock & Wilcox Co. (NYSE: BWC), CenturyLink, Inc. (NYSE: CTL), Humana (NYSE: HUM) and Myriad Genetics (NASDAQ: MYGN) EPS estimates adjusted.

Citigroup (NYSE:C) slashed it EPS estimates on SunPower Co. (SPWRA). They have a “Hold” rating and a price targe of $16.50 on the company.

UBS AG (NYSE:UBS) lowered its EPS estimates on Walt Disney (DIS). They have a “Neutral” rating and a price target of $42.00 on the company.

Citigroup boosted its EPS estimates on General Motors (GM). They have a “Buy” rating and a price target $48.00 on the company.

UBS AG cut its EPS estimates on American Capital (ACAS). They have a “Buy” rating on the company.

JPMorgan Chase & Co. (NYSE:JPM) lowered its EPS estimates on Babcock & Wilcox Co. (BWC). They have a “Neutral” rating and a price target of $28.00 on the company.

UBS AG lowered its EPS estimates on CenturyLink, Inc. (NYSE: CTL). They have a “Buy” rating and a price target of $47.00 on the company.

Morgan Stanley (NYSE:MS) raised its EPS estimates on Humana (HUM). They have an “Equal Weight” rating on the company.

Goldman Sachs (NYSE:GS) cut its EPS estimates on Myriad Genetics (MYGN). They have a “Sell” rating and a price target of $18.00 on the company.

Ratings on (GEVO) (HANS) (MYGN) (NIHD) (NTES) Reiterated

Ratings on shares of Gevo, Inc. (NASDAQ: GEVO), Hansen Natural Co. (NASDAQ: HANS), Myriad Genetics (NASDAQ: MYGN), NII Holdings (NASDAQ: NIHD) and NetScout Systems, Inc. (NASDAQ: NTCT) were reiterated by analysts.

Piper Jaffray (NYSE:PJC) reiterated an “overweight” rating on Gevo, Inc. (GEVO). They have a price target of $31.00 on the company.

Gabelli reiterated a “buy” rating on Hansen Natural Co. (HANS).

Morgan Stanley (NYSE:MS) reiterated an “equal weight” rating on Myriad Genetics (MYGN).

Gabelli reiterated a “buy” rating on NII Holdings (NIHD).

Bank of America (NYSE:BAC) reiterated a “buy” rating on Netease.com Inc (NTES).

Coverage On (JPM) (LRCX) (MS) (MYGN) (RUE) Initiated by Analysts

Analysts have initiated coverage on JPMorgan Chase & Co. (NYSE: JPM), Lam Research Co. (NASDAQ: LRCX), Morgan Stanley (NYSE: MS), Myriad Genetics (NASDAQ: MYGN) and Rue21 (NYSE: RUE).

UBS AG (NYSE:UBS) initiated coverage on JPMorgan Chase & Co. (JPM). They placed a “buy” rating and a price target of $54.00 on the company.

Standpoint Research initiated coverage on Lam Research Co. (LRCX). They placed a “buy” rating and a price target of $60.00 on the company.

UBS AG initiated coverage on Morgan Stanley (MS). They placed a “neutral” rating and a price target of $28.00 on the company.

Auriga initiated coverage on Myriad Genetics (MYGN). They placed a “buy” rating and a price target of $27.00 on the company.

FBR Capital initiated coverage on Rue21 (RUE). They placed a “market perform” rating and a price target of $26.00 on the company.

Myriad Genetics (NASDAQ:MYGN) Downgraded on Lack of Catalysts

Myriad Genetics (NASDAQ:MYGN) was downgraded by Soleil Securities, with the company citing several concerns they have going forward.

Soleil analyst says, "Our Concerns for 2011/12: 1) A maturing BRACAnalysis franchise. 2) Nominal sales contribution from new products. 3) Potential headline risks associated with development challenges for PARP inhibitors and BRACAnalysis companion tests. 4) ACLU patent challenge case...Model Changes: We're looking for FY11 sales of $389.8MM and EPS of $1.01 - for FY12, we're keeping
expectations intact including sales of $415.2MM and EPS of $1.10."

Soleil Securities downgraded Myriad Genetics (MYGN) from Buy
to Hold. Myriad closed Friday at $19.30, dropping $3.11, or 13.88 percent. Soleil lowered their price target on Myriad from $22 to $20.